Euclises: Euclises ups funding round by nearly $1 million

Euclises Pharmaceuticals, the St. Louis-based biotech startup developing cancer treatments, has increased the size of its current funding round from $1.8 million to $2.7 million, according to a filing with the Securities and Exchange Commission. Already, according to the filing, $1.2 million of that has been raised from five unidentified investors. Euclises is developing selective cyclooxygenase-2 ("COX-2) inhibitors to help treat cancer. Previous investors include Cultivation Capital, the BioGenerator,...